Response to: Long-term smoking cessation: from general practice to public health

Response to: Long-term smoking cessation: from general practice to public health Downloaded from https://academic.oup.com/ije/article-abstract/47/4/1356/4994447 by Ed 'DeepDyve' Gillespie user on 16 October 2018 1356 International Journal of Epidemiology, 2018, Vol. 47, No. 4 International Journal of Epidemiology, 2018, 1356 Response to: Long-term smoking doi: 10.1093/ije/dyy084 Advance Access Publication Date: 9 May 2018 cessation: from general practice to public health Gemma MJ Taylor and Neil M Davies* Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK *Corresponding author. Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. E-mail: Neil.Davies@bristol.ac.uk We would like to thank Dr Braillon for his letter about to and attendance at smoking cessation behavioural sup- our study investigating the relative effectiveness of port is not routinely recorded by GPs. varenicline and nicotine replacement therapy (NRT) using Conflict of interest: We work with researchers funded electronic medical records in the Clinical Practice Research by Global Research Awards for Nicotine Dependence Datalink (CPRD). We agree that the CPRD is an abun- (GRAND), which is an Independent Competitive Grants dant resource. About 12% of GP practices in England are Program supported by Pfizer, the manufacturer of 3,4 currently participating in CPRD Gold. varenicline. National Institute for Clinical Excellence guidelines state References that combination-NRT should be prescribed to patients who show a high level of dependence on nicotine or who have 1. Braillon A. Long-term smoking cessation: from general practice to found single forms of NRT inadequate in the past. In our public health. Int J Epidemiol 2018;47:1355. 2. Taylor GMJ, Taylor AE, Thomas KH et al. The effectiveness of study, 23% of patients received more than one prescription varenicline versus nicotine replacement therapy on long-term for NRT. Previous research using data from the NHS Stop smoking cessation in primary care: a prospective cohort study of Smoking Services has found that varenicline is marginally electronic medical records. Int J Epidemiol 2017;46:1948–57. more effective than combination NRT at 4-week follow- 3. Campbell J, Dedman D, Eaton SC, Gallagher AWT. Is the CPRD up[odds ratio, 1.08; 95% confidence interval (CI), 1.00 to GOLD population comparable to the U.K. population? Pharma- 1.16]. A Cochrane review pooled effect estimates from coepidemiol Drug Saf 2013;22:280. seven randomized controlled trials comparing combination- 4. Herrett E, Gallagher AM, Bhaskaran K et al. Data resource pro- file: Clinical Practice Research Datalink (CPRD). Int J Epidemiol with single-NRT, and found that combination-NRT was 2015;44:827–36. more effective (risk ratio, 1.35; 95% CI, 1.11 to 1.63). 5. NICE. Public Health Guideline [PH10] Stop Smoking Services. Programmes of behavioural support for people using 2013. https://www.nice.org.uk/guidance/ph10. smoking cessation medication increase the chances of quit- 6. Brose LS, West R, Stapleton JA. Comparison of the effectiveness of ting (risk ratio, 1.25; 95% CI, 1.08 to 1.45). However, an varenicline and combination nicotine replacement therapy for smok- English survey of smokers conducted between 2006 and ing cessation in clinical practice. Mayo Clinic Proc 2013;88:226–33. 2012 found that only 4.8% of people attempting to quit 7. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessa- smoking had used both prescription pharmacotherapy and tion. Cochrane Database Syst Rev 2012;11:CD000146. specialist behavioural support. In our study, it is possible 8. Stead LF, Koilpillai P, Lancaster T. Additional behavioural sup- that behavioural support was available to patients through port as an adjunct to pharmacotherapy for smoking cessation. primary care-based stop-smoking services, which are pre- Cochrane Database Syst Rev 2015;10:CD009670. dominantly led by practice nurses or smoking cessation 9. Kotz D, Brown J, West R. Prospective cohort study of the effec- advisers. However, our data did not contain information tiveness of smoking cessation treatments used in the “Real on whether patients accessed behavioural support. Referral World”. Mayo Clin Proc 2014;89:1360–67. V The Author 2018; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Epidemiology Oxford University Press

Response to: Long-term smoking cessation: from general practice to public health

Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/response-to-long-term-smoking-cessation-from-general-practice-to-OdgxXCYx3c
Publisher
Oxford University Press
Copyright
© The Author(s) 2018; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association
ISSN
0300-5771
eISSN
1464-3685
D.O.I.
10.1093/ije/dyy084
Publisher site
See Article on Publisher Site

Abstract

Downloaded from https://academic.oup.com/ije/article-abstract/47/4/1356/4994447 by Ed 'DeepDyve' Gillespie user on 16 October 2018 1356 International Journal of Epidemiology, 2018, Vol. 47, No. 4 International Journal of Epidemiology, 2018, 1356 Response to: Long-term smoking doi: 10.1093/ije/dyy084 Advance Access Publication Date: 9 May 2018 cessation: from general practice to public health Gemma MJ Taylor and Neil M Davies* Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK *Corresponding author. Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. E-mail: Neil.Davies@bristol.ac.uk We would like to thank Dr Braillon for his letter about to and attendance at smoking cessation behavioural sup- our study investigating the relative effectiveness of port is not routinely recorded by GPs. varenicline and nicotine replacement therapy (NRT) using Conflict of interest: We work with researchers funded electronic medical records in the Clinical Practice Research by Global Research Awards for Nicotine Dependence Datalink (CPRD). We agree that the CPRD is an abun- (GRAND), which is an Independent Competitive Grants dant resource. About 12% of GP practices in England are Program supported by Pfizer, the manufacturer of 3,4 currently participating in CPRD Gold. varenicline. National Institute for Clinical Excellence guidelines state References that combination-NRT should be prescribed to patients who show a high level of dependence on nicotine or who have 1. Braillon A. Long-term smoking cessation: from general practice to found single forms of NRT inadequate in the past. In our public health. Int J Epidemiol 2018;47:1355. 2. Taylor GMJ, Taylor AE, Thomas KH et al. The effectiveness of study, 23% of patients received more than one prescription varenicline versus nicotine replacement therapy on long-term for NRT. Previous research using data from the NHS Stop smoking cessation in primary care: a prospective cohort study of Smoking Services has found that varenicline is marginally electronic medical records. Int J Epidemiol 2017;46:1948–57. more effective than combination NRT at 4-week follow- 3. Campbell J, Dedman D, Eaton SC, Gallagher AWT. Is the CPRD up[odds ratio, 1.08; 95% confidence interval (CI), 1.00 to GOLD population comparable to the U.K. population? Pharma- 1.16]. A Cochrane review pooled effect estimates from coepidemiol Drug Saf 2013;22:280. seven randomized controlled trials comparing combination- 4. Herrett E, Gallagher AM, Bhaskaran K et al. Data resource pro- file: Clinical Practice Research Datalink (CPRD). Int J Epidemiol with single-NRT, and found that combination-NRT was 2015;44:827–36. more effective (risk ratio, 1.35; 95% CI, 1.11 to 1.63). 5. NICE. Public Health Guideline [PH10] Stop Smoking Services. Programmes of behavioural support for people using 2013. https://www.nice.org.uk/guidance/ph10. smoking cessation medication increase the chances of quit- 6. Brose LS, West R, Stapleton JA. Comparison of the effectiveness of ting (risk ratio, 1.25; 95% CI, 1.08 to 1.45). However, an varenicline and combination nicotine replacement therapy for smok- English survey of smokers conducted between 2006 and ing cessation in clinical practice. Mayo Clinic Proc 2013;88:226–33. 2012 found that only 4.8% of people attempting to quit 7. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessa- smoking had used both prescription pharmacotherapy and tion. Cochrane Database Syst Rev 2012;11:CD000146. specialist behavioural support. In our study, it is possible 8. Stead LF, Koilpillai P, Lancaster T. Additional behavioural sup- that behavioural support was available to patients through port as an adjunct to pharmacotherapy for smoking cessation. primary care-based stop-smoking services, which are pre- Cochrane Database Syst Rev 2015;10:CD009670. dominantly led by practice nurses or smoking cessation 9. Kotz D, Brown J, West R. Prospective cohort study of the effec- advisers. However, our data did not contain information tiveness of smoking cessation treatments used in the “Real on whether patients accessed behavioural support. Referral World”. Mayo Clin Proc 2014;89:1360–67. V The Author 2018; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association

Journal

International Journal of EpidemiologyOxford University Press

Published: Aug 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off